Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection

Authors: Lauren Fusfeld, Jyoti Aggarwal, Carly Dougher, Montserrat Vera-Llonch, Stephen Bubb, Mrudula Donepudi, Thomas F Goss

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Infection with hepatitis C virus (HCV) is associated with high morbidity and increased mortality but many patients avoid initiation of treatment or report challenges with treatment completion. The study objective was to identify motivators and barriers for treatment initiation and completion in a community sample of HCV-infected patients in the United States.

Methods

Survey methods were employed to identify factors reported by patients as important in their decision to start or complete HCV treatment. Study participants included 120 HCV-infected individuals: 30 had previously completed treatment with pegylated interferon/ribavirin (PR), 30 had discontinued PR, 30 were treated with PR at the time of the survey, and 30 were treatment‒naïve. Telephone interviews occurred between May and August of 2011 and employed a standardized guide. Participants assigned factors a rating from 1 (not at all important) to 5 (extremely important). Trained researchers coded and analyzed interview transcripts.

Results

Of 33 factors, expected health problems from not treating HCV infection was reported as most encouraging for treatment initiation and completion, while treatment side effects was most discouraging. Sixty-nine percent of participants reported that the ability to obtain information during treatment on the likelihood of treatment success (i.e., results of viral load testing) would motivate them to initiate therapy. Median preferred timing for learning about test results was 5 weeks (range: 1–23 weeks).

Conclusion

Understanding challenges and expectations from patients is important in identifying opportunities for education to optimize patient adherence to their HCV treatment regimen.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chack E, Talal AH, Sherman KE, Schiff ER, Saab S: Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011, 31 (8): 1090-1101. 10.1111/j.1478-3231.2011.02494.x.CrossRef Chack E, Talal AH, Sherman KE, Schiff ER, Saab S: Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011, 31 (8): 1090-1101. 10.1111/j.1478-3231.2011.02494.x.CrossRef
4.
go back to reference National Research Council: Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. 2010, Washington, DC: The National Academies Press National Research Council: Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. 2010, Washington, DC: The National Academies Press
5.
go back to reference Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011, 54 (4): 1433-1444. 10.1002/hep.24641.CrossRefPubMedPubMedCentral Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011, 54 (4): 1433-1444. 10.1002/hep.24641.CrossRefPubMedPubMedCentral
6.
go back to reference Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009, 49 (4): 1335-1374. 10.1002/hep.22759.CrossRefPubMed Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009, 49 (4): 1335-1374. 10.1002/hep.22759.CrossRefPubMed
7.
go back to reference Bacon BR, Mchutchison JG: Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care. 2005, 11 (Suppl 10): S296-S306.PubMed Bacon BR, Mchutchison JG: Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care. 2005, 11 (Suppl 10): S296-S306.PubMed
8.
go back to reference Fraenkel L, Mcgraw S, Wongcharatrawee S, Garcia-tsao G: What do patients consider when making decisions about treatment for hepatitis C?. Am J Med. 2005, 118 (12): 1387-1391. 10.1016/j.amjmed.2005.05.029.CrossRefPubMed Fraenkel L, Mcgraw S, Wongcharatrawee S, Garcia-tsao G: What do patients consider when making decisions about treatment for hepatitis C?. Am J Med. 2005, 118 (12): 1387-1391. 10.1016/j.amjmed.2005.05.029.CrossRefPubMed
9.
go back to reference Strathdee SA, Latka M, Campbell J: Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005, 40 (Suppl 5): S304-S312.CrossRefPubMedPubMedCentral Strathdee SA, Latka M, Campbell J: Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005, 40 (Suppl 5): S304-S312.CrossRefPubMedPubMedCentral
10.
go back to reference Mcnally S, Temple-smith M, Sievert W, Pitts MK: Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Public Health. 2006, 30 (5): 422-427. 10.1111/j.1467-842X.2006.tb00457.x.CrossRefPubMed Mcnally S, Temple-smith M, Sievert W, Pitts MK: Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Public Health. 2006, 30 (5): 422-427. 10.1111/j.1467-842X.2006.tb00457.x.CrossRefPubMed
11.
go back to reference Khokhar OS, Lewis JH: Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?. Dig Dis Sci. 2007, 52 (5): 1168-1176. 10.1007/s10620-006-9579-1.CrossRefPubMed Khokhar OS, Lewis JH: Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?. Dig Dis Sci. 2007, 52 (5): 1168-1176. 10.1007/s10620-006-9579-1.CrossRefPubMed
12.
go back to reference Treloar C, Holt M: Drug treatment clients‘ readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Aust Health Rev. 2008, 32 (3): 570-576. 10.1071/AH080570.CrossRefPubMed Treloar C, Holt M: Drug treatment clients‘ readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Aust Health Rev. 2008, 32 (3): 570-576. 10.1071/AH080570.CrossRefPubMed
13.
go back to reference Grebely J, Genoway KA, Raffa JD: Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008, 93 (1–2): 141-147.CrossRefPubMed Grebely J, Genoway KA, Raffa JD: Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008, 93 (1–2): 141-147.CrossRefPubMed
14.
go back to reference Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J: Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002, 35 (3): 704-708. 10.1053/jhep.2002.31311.CrossRefPubMed Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J: Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002, 35 (3): 704-708. 10.1053/jhep.2002.31311.CrossRefPubMed
15.
go back to reference Mchutchison JG, Manns M, Patel K: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002, 123 (4): 1061-1069. 10.1053/gast.2002.35950.CrossRefPubMed Mchutchison JG, Manns M, Patel K: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002, 123 (4): 1061-1069. 10.1053/gast.2002.35950.CrossRefPubMed
16.
go back to reference Lore V, Amorosa VK, Localio AR: Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis. 2009, 48 (2): 186-193. 10.1086/595685.CrossRef Lore V, Amorosa VK, Localio AR: Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis. 2009, 48 (2): 186-193. 10.1086/595685.CrossRef
18.
go back to reference Jenner A, Scott A: Circulating beliefs, resilient metaphors and faith in biomedicine: hepatitis C patients and interferon combination therapy. Sociol Health Illn. 2008, 30 (2): 197-216. 10.1111/j.1467-9566.2007.01061.x.CrossRefPubMed Jenner A, Scott A: Circulating beliefs, resilient metaphors and faith in biomedicine: hepatitis C patients and interferon combination therapy. Sociol Health Illn. 2008, 30 (2): 197-216. 10.1111/j.1467-9566.2007.01061.x.CrossRefPubMed
19.
go back to reference Cotler SJ, Patil R, Mcnutt RA: Patients‘ values for health states associated with hepatitis C and physicians’ estimates of those values. Am J Gastroenterol. 2001, 96 (9): 2730-2736. 10.1111/j.1572-0241.2001.04132.x.CrossRefPubMed Cotler SJ, Patil R, Mcnutt RA: Patients‘ values for health states associated with hepatitis C and physicians’ estimates of those values. Am J Gastroenterol. 2001, 96 (9): 2730-2736. 10.1111/j.1572-0241.2001.04132.x.CrossRefPubMed
20.
go back to reference Evon DM, Simpson K, Kixmiller S: A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011, 106 (10): 1777-1786. 10.1038/ajg.2011.219.CrossRefPubMedPubMedCentral Evon DM, Simpson K, Kixmiller S: A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011, 106 (10): 1777-1786. 10.1038/ajg.2011.219.CrossRefPubMedPubMedCentral
21.
go back to reference Munoz-plaza CE, Strauss S, Astone-twerell J: Exploring drug users’ attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. Int J Drug Policy. 2008, 19 (1): 71-78. 10.1016/j.drugpo.2007.02.003.CrossRefPubMed Munoz-plaza CE, Strauss S, Astone-twerell J: Exploring drug users’ attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. Int J Drug Policy. 2008, 19 (1): 71-78. 10.1016/j.drugpo.2007.02.003.CrossRefPubMed
22.
go back to reference Jessop AB, Cohen C, Burke MM, Conti M, Black M: Hepatitis support groups: meeting the information and support needs of hepatitis patients. Gastroenterol Nur. 2004, 27 (4): 163-169. 10.1097/00001610-200407000-00004.CrossRef Jessop AB, Cohen C, Burke MM, Conti M, Black M: Hepatitis support groups: meeting the information and support needs of hepatitis patients. Gastroenterol Nur. 2004, 27 (4): 163-169. 10.1097/00001610-200407000-00004.CrossRef
23.
go back to reference Sylvestre DL, Zweben JE: Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy. 2007, 18 (5): 406-410. 10.1016/j.drugpo.2007.01.010.CrossRefPubMed Sylvestre DL, Zweben JE: Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy. 2007, 18 (5): 406-410. 10.1016/j.drugpo.2007.01.010.CrossRefPubMed
Metadata
Title
Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection
Authors
Lauren Fusfeld
Jyoti Aggarwal
Carly Dougher
Montserrat Vera-Llonch
Stephen Bubb
Mrudula Donepudi
Thomas F Goss
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-234

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine